Effects of short-term testosterone administration on variables of the metabolic syndrome, in particular aldosterone.
Abstract Background: The ATPIII criteria of the metabolic syndrome (MS) comprise impaired fasting glucose (>5.6 nmol/L), waist circumference >102 cm, hypertension (>130/85 mm Hg), high triglycerides (>1.7 nmol/L) and low HDL cholesterol (≤1.03 nmol/L). Aldosterone is currently recognized as a key factor in the pathogenesis of cardiovascular diseases and insulin resistance, linking hypertension to MS and obesity. Further, the MS is related to psychological functioning. Forty-two men older than 40 years with BMI >30 kg/m2, chronic heart failure (CHF) and serum testosterone (T) <12.0 nmol/L were recruited. Of these 42, 26 consented to T treatment and received two injections with T undecanoate 1000 mg. Biochemical variables relevant for the MS and also serum aldosterone were determined before and after injections; an echocardiography and Aging Males' Symptoms (AMS) scale were also utilized. After 24 weeks of testosterone administration, there were significant declines of insulin and homeostatic model assessment and of serum aldosterone, but no changes in blood pressure. Serum glucose declined but not significantly (p=0.073). There was a slight increase in LDL cholesterol and a decrease in triglycerides. Other variables of MS and other biochemical variables did not change. Echocardiographical variables did not change. The AMS showed improvements over the first 3 months after testosterone administration but, although sustained, there was no further improvement. Short-term testosterone administration over 24 weeks led to some improvements of variables of the MS, notably of aldosterone. Longer-term studies are needed to analyze whether the decrease in serum aldosterone will improve blood pressure and glycemic control.